Neutralizing antibodies to sclerostin have had great success in phase III trials for postmenopausal osteoporosis [7], and a sclerostin neutralizing antibody—Romosozumab—was recently approved for clinical use in Japan, the US, South Korea, Canada, and Australia [8]. This evidence concerns the gene SOST and postmenopausal osteoporosis.